SAGE PRO

Home / Research / Cohance Lifesciences Limited

SAGE PRO · ORIGINAL EQUITY RESEARCH

Cohance Lifesciences Limited — Q2 FY27 Results Analysis

WATCH: recovery not established

Published · Quarter Q2 FY27 · COHANCE

Price₹457.60
FY26 P/E97.7x
COMPANY-SPECIFIC GRAPHICAL SUMMARY

What the reported figures reveal

CHART 1

12.9% sequential recovery

Q2 FY26₹555.57 cr
Q1 FY27₹422.26 cr
Q2 FY27₹476.65 cr

Issuer Q2 statutory results / presentation / analyst calculation

CHART 2

18.6% decline

H1 FY26₹1,104.88 cr
H1 FY27₹898.91 cr

Issuer Q2 statutory results / presentation / analyst calculation

CHART 3

API+ 56%

API+56%
Pharma CDMO35%
Specialty9%

Issuer Q2 statutory results / presentation / analyst calculation

CHART 4

Business divergence

Sapala33.6 % YoY
API+6.2 % YoY
Pharma CDMO-27.4 % YoY
Specialty-40.6 % YoY

Issuer Q2 statutory results / presentation / analyst calculation

ORIGINAL RESEARCH INSIGHTS

Investment findings and watch points

RESEARCH INSIGHT

WATCH: recovery not established

Q2 better sequentially, H1 earnings depressed

Watch: Require recurring cash

RESEARCH INSIGHT

12.9% sequential recovery

Still down 14.2% YoY

Watch: Track H2 deliveries

RESEARCH INSIGHT

18.6% decline

H2 recovery needed

Watch: Compare cumulative sales

RESEARCH INSIGHT

API+ 56%

Rounded management mix

Watch: Track business contribution

FULL PUBLISHED RESEARCH

Earnings and management commentary analysis

SAGE PRO Institutional Research | 16 November 2026 | Q2 FY2027 | NSE: COHANCE

1. Investment decision

Key takeaways

  • WATCH — sequential recovery, but capital returns remain unproven. Cohance combines small molecules, nucleic-acid chemistry, ADCs, APIs and specialty chemicals.
  • The integrated platform must demonstrate repeat customer demand, operating profit and cash rather than just acquired capabilities.

Q2 consolidated operating revenue was ₹476.65 crore, up 12.9% QoQ but down 14.2% YoY. Management reported EBITDA ₹35.5 crore versus ₹1.2 crore in Q1; adjusted EBITDA ₹45.9 crore (9.6% margin), versus ₹9.2 crore (2.2%).

H1 revenue declined 18.6% and reported EBITDA fell 84%. The critical accounting insight is that parent-attributable Q2 PAT ₹15.22 crore is not group operating profit: group PBT was negative ₹10.75 crore, a net tax benefit produced group PAT of ₹2.27 crore, and losses allocated to minorities of ₹12.95 crore raised parent profit.

An annualised Q2 P/E would misrepresent recurring economics.

At ₹457.60 (Sage PRO financial data, 16 November 2026, ~16:30 IST), September 38.26 crore shares imply ₹17,508 crore equity value and FY26 parent PAT ₹179.23 crore implies 97.7x. H1 loss makes run-rate P/E unhelpful. WATCH over 12–24 months.

Variant thesis: commercial reloads, Sapala and ADC integration can restore absorption; destocking, safety/regulatory issues and underutilised assets may delay returns. H2 growth is the immediate test. Source-verified longform; full QA open.

2. Business economics and competitive advantage

Small molecules

Cohance's Pharma CDMO develops and manufactures innovator molecules. Scientific contribution can include route optimisation, scale-up, impurity control and validation. Process continuity and customer qualification can support repeat business, but the customer controls product development, launch, supplier allocation and end-market demand. Commercial orders can be lumpy because clients change inventories and shipment timing. Management reported better Q3/Q4 small-molecule reloads, two new commercial lateral programmes and one Phase III award, with 19 commercial and 11 Phase III programmes. Cohance standalone commercial revenue was approximately 78%, not the group's commercial sales share. Count awards as progress, not as a disclosed revenue backlog. Track repeat batches, aggregate programme revenue and actual technology transfer.

Key takeaways

  • ADC and nucleic acids: H1 destocking affected two commercial ADC programmes.
  • NJ Bio completed two GMP campaigns; breakeven and early FY28 bioconjugation availability are not guaranteed profitable utilisation.
  • Sapala's specialised building blocks grew 33.6% Q2 and ~83% H1 without Q2 early Phase III supplies.

Niche technologies were 13.7% of Q2 sales, not all Sapala. Linker/payload and bioconjugation integration may expand client work, but require qualified repeat orders. Compare with Anthem/Sai integrated research-manufacturing and Neuland CMS/API using operating margin, cash and incremental returns, not an unverified sector multiple.

API+ and specialty chemicals

API+ combines established API and formulations businesses. Q2 sales rose 6.2% YoY with selective pricing; lower API volume, shipment phasing and raw-material inflation pressured margins. API+ accounted for 56% of rounded Q2 group mix; Pharma CDMO 35%, specialty chemicals 9%. At ₹476.65 crore group sales, implied contributions are about ₹267/167/43 crore, not separately audited statutory segments. Pharma CDMO declined 27.4% YoY and specialty chemicals 40.6%; the latter reflects agrochemical volume, pricing and phasing, while performance materials were relatively stable. Group CDMO share of 44% includes specialty chemicals, so avoid interpreting the full 44% as pharmaceutical CDMO. Ind AS 108 statutory reporting is one operating segment. Separate growth, mix and margin by management activity where disclosed; do not fabricate segment operating profits.

3. Consolidated results and earnings quality

Key takeaways

  • ₹ crore, statutory consolidated accounts; issuer presentation figures in ₹ million converted to crore.
  • Reported perimeter retained; not a reconstructed organic series.
MetricQ2 FY27Q1 FY27Q2 FY26H1 FY27H1 FY26FY26
Operating revenue476.65422.26555.57898.911104.882268.55
Other income12.4112.2515.6024.6629.7734.09
Materials + inventory changes139.09120.28141.13259.37289.27662.63
Employee expense153.54132.96126.72286.50260.04507.71
Other expense148.64167.86166.77316.50322.61671.22
Derived operating EBITDA35.381.16120.9536.54232.96426.99
D&A50.1749.5444.0299.7189.16187.33
Finance expense8.376.748.7615.1118.9437.24
PBT pre exception-10.75-42.8783.77-53.62154.63236.51
Exceptional charge00008.1029.47
Group PAT2.27-45.1966.39-42.92112.79150.12
Parent PAT15.22-24.1274.08-8.90122.96179.23
Basic EPS ₹0.40-0.631.94-0.233.224.69

Operating EBITDA is revenue less materials/inventory, employee and other expenses, excluding other income. Q2 ₹35.38 + ₹12.41 other income − ₹50.17 D&A − ₹8.37 finance = negative ₹10.75 crore PBT. The presentation reports EBITDA ₹35.5 crore, Q2 FY26 ₹122.6 crore and H1 ₹36.7 crore vs ₹234.8 crore.

Differences reflect issuer classifications/rounding; the statutory-derived series is used consistently rather than forcing equality. Management's adjusted EBITDA adds ₹3.6 crore FX mark-to-market adjustment and ₹6.8 crore one-time items, reaching ₹45.9 crore.

Q1 adjusted ₹9.2 crore; H1 ₹55.1 crore versus prior H1 ₹262.9 crore. Merger and ESOP adjustments may help comparison, but recurring integration and stock-compensation costs are real owner economics.

Operating leverage

Q2 sales rose ₹54.39 crore sequentially. Materials and inventory costs increased ₹18.81 crore, staff ₹20.58 crore, other expense declined ₹19.22 crore. Derived EBITDA improved ₹34.22 crore, an incremental margin about 63% from a weak base, not a permanent forward margin. YoY sales fell ₹78.92 crore; employee expenses rose ₹26.82 crore; materials/inventory fell ₹2.04 crore, other expense fell ₹18.13 crore. Operating EBITDA declined ₹85.57 crore. This is operating deleverage: scientific, manufacturing and integration resources did not shrink proportionately to revenue. Q2 recovery is encouraging but margin remains well below prior year. Material margin 70.8% vs 74.6% reflects mix, raw-material inflation and weaker commercial contribution. Statutory inventory change was a ₹97.55 crore credit vs ₹50.47 crore prior year. Combined cost and cash inventory movement are more informative than treating accounting inventory credits as permanent cash savings.

Tax and minority allocation

Q2 net tax benefit ₹13.02 crore includes ₹13.82 crore prior-year current tax credit, current tax ₹1.43 crore and deferred tax benefit ₹0.63 crore. Group PAT ₹2.27 crore, NCI loss ₹12.95 crore, parent PAT ₹15.22 crore. Removing the prior-year credit alone yields group loss ₹11.55 crore, an arithmetic sensitivity rather than audited adjusted profit. H1 group loss ₹42.92 crore, NCI loss ₹34.02 crore and parent loss ₹8.90 crore. FY26 group PAT ₹150.12 crore vs parent ₹179.23 crore. When subsidiaries become profitable, positive minority shares reduce parent earnings. Forecast attributable profit on normal tax and explicit minority assumptions, not recurring tax credits or NCI losses. Q2 adjusted PAT ₹7.4 crore as presented is not the same measure as group or parent statutory PAT.

H2 hurdle

FY26 operating revenue ₹2,268.55 crore less H1 FY26 ₹1,104.88 crore implies H2 ₹1,163.67 crore. H1 FY27 ₹898.91 crore. Flat FY27 revenue requires H2 ₹1,369.64 crore, +17.7% YoY and +52.4% vs H1. A 5% FY27 decline requires H2 ₹1,256.21 crore, +8.0% YoY. Repeating Q2 twice yields FY27 ₹1,852.21 crore, -18.4%. Management's positive H2 YoY outlook requires average quarterly sales above ₹581.84 crore, 22% above Q2, but does not necessarily imply flat annual sales. FY26 H2 derived EBITDA ₹194.03 crore; exceeding that at ₹1,163.67 crore sales requires >16.7% margin. This statutory hurdle differs from management's adjusted-EBITDA guidance; compare both on consistent definitions.

4. Cash flow, balance sheet and capital allocation

Key takeaways

  • H1 consolidated CFO ₹188.06 crore versus ₹261.14 crore, despite group loss.
  • The source of cash matters: pre-working-capital operating profit only ₹39.20 crore versus ₹239.42 crore; receivable release ₹230.59 crore and liability benefit ₹73.55 crore offset ₹172.03 crore inventory use.
  • Net tax cash positive ₹16.75 crore (refunds exceed payments).

The positive cash flow is not proof of sustainable earnings recovery. Receivable release from a high opening balance and tax refunds cannot be extrapolated indefinitely.

H1 cash flow ₹crFY27FY26
Pre-working-capital operating profit39.20239.42
Inventory movement-172.03-125.51
Receivables release230.59205.58
Payables/other liabilities73.552.92
Cash generated before tax171.31322.41
Net tax cash flow16.75-61.27
CFO188.06261.14
Physical capital purchases108.0189.71
CFO less capital purchases80.05171.43

The cash proxy after physical capex declined about 53%; excludes financing, acquisition expenditure and sale proceeds. Management's Q2 free cash flow ₹133.8 crore uses a different period/definition, and H1 capex deployed ₹107.7 crore is close to statutory ₹108.01 crore purchases; do not subtract both.

H1 cash statement also records ₹44.96 crore subsidiary investment net of acquired cash, and ₹124.40 crore acquisition of additional subsidiary interest in financing. Deducting both from the simple ₹80.05 crore cash proxy gives negative ₹89.31 crore before other financing/investments.

This is an illustrative deployment bridge, not audited FCFE. Cash increased to ₹98.63 crore from ₹49.14 crore due also to investment and financing movements. A positive cash balance is not a substitute for recurring operating cash.

Working capital and funding

September inventory ₹734.34 crore vs March ₹562.23; receivables ₹469.02 vs ₹681.01; trade payables ₹364.32 vs ₹284.58. Narrow trade working capital fell from ₹958.66 to ₹839.04 crore, but inventory increased 30.6%. Receivables are roughly 95 days of annualised H1 sales, an ending-balance proxy, not contractual DSO. Inventory exceeds 40% of annualised H1 sales. Track ageing, customer-linked batches, shipment conversion and payment terms. Inventory can support stronger future deliveries or tie up capital if demand slips. Payable extensions and receivable collection may not repeat. Current assets ₹1,716.73 crore/current liabilities ₹865.39 crore imply 1.98x current ratio vs 2.78x in March; this is not cash coverage.

September borrowings ₹227.70 crore vs ₹169.67 crore March; leases ₹220.71 crore. Cash ₹98.63 crore, current investments ₹185.12 crore and other bank balances ₹9.18 crore approximate management cash-on-books ₹294.3 crore. Goodwill ₹1,290.19 crore is 22.7% of assets ₹5,680.18 crore; CWIP ₹215.81 crore. Acquisition returns and impairment matter.

Acquisitions and the return hurdle

The statutory note records additional 65% Aaruka Bio stake for ₹47.89 crore, ownership 90%, control from 19 September. Accounted for as asset acquisition under Ind AS 103, not business combination. Do not assume full-quarter recurring acquired revenue. Additional 11.3% NJ Bio interest cost ₹124.40 crore, raising ownership to 67.3%; related put-option liability and NCI derecognised. Increased ownership changes attributable earnings and cash exposure even at unchanged group operating profit. Compare acquisition economics using full invested capital, goodwill, lease obligations and actual subsidiary cash generation. The company plans phased capability investment in bioconjugation, payload/linker, R&D, quality, safety and maintenance; a total quantified programme is not disclosed in Q2. On hypothetical ₹500 crore incremental productive investment, a 15% after-tax return needs ₹100 crore EBIT at 25% tax; with ₹25–40 crore depreciation, ₹125–140 crore EBITDA requires ₹500–560 crore sales at 25% margin. Not guidance. Track maintenance/compliance separately from growth and qualify actual assets before assuming return.

5. Management execution, safety and measurable milestones

Key takeaways

  • Q1 was the trough, Q2 sequential improvement and H2 expected YoY growth.
  • Test actual commercial shipments, recurring ADC demand, NJ Bio utilisation, Sapala scale, API+ volume/price and specialty demand.
  • Signed agreements, qualified processes and collected cash are distinct milestones.

Safety and regulatory exposure

Management acknowledged a fatal incident involving a colleague at Suryapet and a closure order, with corrective/preventive action begun and further impact under assessment. The human loss is serious independent of financial consequences. No assumption of reopening, independently established cause or quantified full exposure is made. Monitor official investigation and closure/restart orders, remedial actions, worker safety, customer continuity and any liabilities. Cost reduction must not compromise quality or safety. Management also reported US FDA inspections at Pashamylaram, Shamshabad and Jaggayyapeta, responses submitted and CAPA ongoing. Submission does not prove regulatory closure or a clean inspection. Verify official classifications and follow-up disclosures. Regulatory and safety spending may be necessary while profitability is depressed; do not treat compliance as a discretionary cost lever.

6. Valuation and FY28 scenarios

Key takeaways

  • Reference ₹457.60, September 38.26 crore shares, equity value ~₹17,508 crore.
  • FY26 parent PAT ₹179.23 crore implies 97.7x.
  • Narrow EV = equity + ₹227.70 crore borrowings − ₹98.63 crore cash = ₹17,637 crore, excluding leases, minority interests, other liabilities and investments.

FY26 derived operating EBITDA ₹426.99 crore gives 41.3x narrow EV/EBITDA. It is a directional metric, not fully comparable EV. Parent earnings are the clearer basis; model 38.5 crore shares, normal tax and explicit positive minority profit rather than capitalise tax refunds and subsidiary losses.

FY28 assumption (₹cr except EPS/price)BearBaseBull
Operating revenue240030003600
Operating EBITDA margin12%20%27%
Operating EBITDA288600972
Other income252525
D&A200220240
Finance cost403535
PBT73370722
Group PAT at 25% tax54.75277.50541.50
NCI profit51020
Parent PAT49.75267.50521.50
EPS on 38.5cr shares1.296.9513.55
Terminal P/E assumption30x45x50x
Indicative price ₹39313677
Change vs reference-91%-32%+48%

Bear assumes weak utilisation and integration, base assumes revenue CAGR ~15% from FY26 and a 20% derived margin versus FY26 18.8%, bull ~26% CAGR, 27% margin and major commercial contribution. These are independent analyst cases, not company guidance, consensus or probability-weighted price targets.

Dividends and discounting excluded. Base parent PAT rises to ₹267.5 crore yet price is below reference; the starting multiple makes earnings recovery insufficient by itself. Bull requires both a stronger business and a premium valuation.

At base EPS ₹6.95, reference requires ~65.8x FY28 earnings merely to preserve price.

Reverse valuation at 45x: required EPS ₹10.17, parent PAT ₹391.5 crore on 38.5 crore shares. Add ₹10 crore NCI profit, group PAT ₹401.5 crore; at 25% tax PBT ₹535.3 crore. With base D&A ₹220 crore, finance ₹35 crore and other income ₹25 crore, operating EBITDA required ₹765.3 crore.

At 20% margin sales ₹3,826 crore, roughly 30% two-year CAGR from FY26. At 25% margin hurdle ₹3,061 crore, at 15% ₹5,102 crore. At EPS ₹5, 30x/40x/50x implies ₹150/200/250; ₹8 gives ₹240/320/400; ₹12 gives ₹360/480/600.

Each incremental ₹100 crore revenue at 25% margin and 25% tax adds ₹18.75 crore group PAT before extra depreciation/interest, ~₹0.49 EPS if all attributable, ₹21.9 at 45x. A full DCF needs subsidiary-specific economics, capex and working capital, tax and liabilities; cash released in H1 cannot be annualised as steady owner cash.

No unverified peer multiple or precise DCF is asserted.

7. Risks, catalysts and original evidence

Catalysts: Q3/Q4 small-molecule deliveries, positive H2 YoY revenue and EBITDA, ADC reloads, NJ Bio progress toward breakeven, recurring Sapala demand, API+ recovery and improving specialty orders. Require group pre-tax profit, reported margin, cash before temporary working-capital releases and verified safety/regulatory progress. Risks: commercial customer concentration, clinical failure and shipment deferral; continued ADC destocking; API cost inflation and agrochemical pricing/volume; acquisition integration and goodwill impairment; changing NCI; Suryapet closure/restart and inspection CAPA; inventory and tax-refund-dependent cash; capital ahead of demand; multiple compression.

These can occur together. WATCH until better earnings/cash or price improves the risk-reward. Do not use a sentiment score or a signed award alone as a purchase instruction.

Source ledger

S1. Cohance Q2/H1 statutory consolidated results and board outcome, 6 November 2026: . P&L, balance sheet, cash flows and notes 4–6 anchor figures, tax, NCI and acquisitions. Original table text accessible; screenshot retrieval failed.

S2. Issuer investor presentation, 6 November: . Canonical 76364, current semantic ACCEPT. Financial highlights, mix, adjusted EBITDA, cash/capex and H2 outlook.

S3. Call held 6 November, filed 11 November: https://nsearchives.nseindia.com/corporate/SUVENPHARMSUSHEEL_11112026175134_Cohance_Q2_FY27_concall_transcript.pdf . Canonical 88449, current semantic ACCEPT. Management discussion of reloads, awards, ADC destocking, Sapala, capacity, safety and inspection responses.

S4. Exchange board outcome and issuer release: https://nsearchives.nseindia.com/corporate/SUVENPHARMSUSHEEL_06112026174827_Cohance_Outcome_BM_06112026_uploading.pdf . S5. Sage PRO current quote ₹457.60, financial data, 16 November 2026; refresh before trading.

Key takeaways

  • Independent full original-page QA, comparable peer valuation, acquisition-level return and complete owner-cash DCF remain outstanding.
  • All FY28 inputs and return hurdles are explicitly analyst assumptions.
  • This source-verified original longform is not full institutional QA certification.

Additional company evidence

CHART 5

Nucleic acid growth

Q233.6 % YoY
H183 % YoY

Issuer Q2 statutory results / presentation / analyst calculation

CHART 6

Recovery from trough

Q2 FY26₹120.95 cr
Q1 FY27₹1.16 cr
Q2 FY27₹35.38 cr

Issuer Q2 statutory results / presentation / analyst calculation

CHART 7

Adjusted versus reported

Q2 FY26 adjusted23.2%
Q1 FY27 adjusted2.2%
Q2 FY27 adjusted9.6%
Q2 FY27 reported7.4%

Issuer Q2 statutory results / presentation / analyst calculation

CHART 8

Tax and NCI matter

PBT₹-10.75 cr
Group PAT₹2.27 cr
Parent PAT₹15.22 cr

Issuer Q2 statutory results / presentation / analyst calculation

SOURCE REFERENCES

Original disclosures and investor presentations

  1. Q2 earnings call

Related research and comparisons

Other published Q2 FY27 reports

This is dated research, not a live market quote. Scenarios and historical performance are not guarantees.